Ahmed Daak

Sanofi (France) — France

Medicine · Health Sciences

16h-index846citations63works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Platelet Disorders and Treatments(20), Chronic Lymphocytic Leukemia Research(19), Hemoglobinopathies and Related Disorders(15), Autoimmune Bullous Skin Diseases(10), Fatty Acid Research and Health(7)

Publications63 total

Essai de phase 3 LUNA3 : premier rapport d’efficacité/sécurité d’emploi de la période d’extension à long terme avec le rilzabrutinib chez des adultes atteints de thrombopenie immunologique persistante/chronique (PTI)
La Revue de Médecine Interne·2025
Réponse plaquettaire selon les critères du groupe de travail international (IWG) pour le rilzabrutinib versus placebo dans l’étude LUNA3 chez des patients atteints de PTI primaire
La Revue de Médecine Interne·2025
Investigating patients' experiences with dyspnea associated with warm antibody hemolytic anemia (wAIHA) and cognitive debriefing of the FACIT-dyspnea 10 item short form: A qualitative patient interview study
Blood·2025Open Access
Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent/chronic immune thrombocytopenia in the long-term extension period of the Phase 3 LUNA3 study
Blood·2025Open Access
Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design
Blood·2025
Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)
Blood·2025Open Access
Reproductive health in patients with primary immune thrombocytopenia (ITP) receiving rilzabrutinib: A subgroup analysis from the Phase 3 LUNA3 multicenter study
Blood·2025
Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)
Blood·2025
Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up
Blood·2025
Early multi-immune modulation with rilzabrutinib in patients with primary ITP after first-line treatment failure: A phase 3b study (LUNA 4)
Blood·2025
A randomized, double-blind, placebo-controlled trial of a novel BTK inhibitor (rilzabrutinib) in patients with sickle cell disease (SCD) aged 10–65 years: LIBRA Study
Blood·2025· 1 citedOpen Access
A Qualitative Study on Patient Experience with Signs, Symptoms, and Daily Impacts of Immune Thrombocytopenia
Patient·2025Open Access
Exploring patients’ experiences with wAIHA and the content validity of the FACIT-fatigue: a qualitative interview study
Orphanet Journal of Rare Diseases·2025Open Access
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
Blood·2025· 28 citedOpen Access
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study
American Journal of Hematology·2025· 10 citedOpen Access
Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
Blood·2024· 3 citedOpen Access
Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease
Blood·2024· 3 citedOpen Access
Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study
Blood·2024· 3 citedOpen Access
Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
Blood·2024· 10 citedOpen Access
Cognitive impairment among patients with chronic immune thrombocytopenia
British Journal of Haematology·2024· 6 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

David J. Kuter(14), Kebreab Ghebremeskel(13), Nichola Cooper(13), Waleed Ghanima(10), Adrián L. Rabinowicz(9), Mustafa I. Elbashir(8), Mengjie Yao(7), Miguel A. López‐Toledano(6), Howard A. Liebman(6), Frederick D. Sancilio(6), Matias Cordoba(5), Remco Diab(5), Þorsteinn Thorsteinsson(5), Terry Gernsheimer(5), Jiřı́ Mayer(5), Mamta Garg(5), A.J. Gerard Jansen(5), Robert Bird(5), Milan Košťál(5), Yoshitaka Miyakawa(4)